Karyopharm Therapeutics Inc.'s (KPTI) CEO Richard Paulson on Q3 2021 Results - Earnings Call Transcript

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q3 2021 Earnings Conference Call November 3, 2021 8:30 AM ET

Company Participants

Jason Finkelstein - Argot Partners
Richard Paulson - President & Chief Executive Officer
Sohanya Cheng - Senior Vice President-Sales & Commercial Operations
Jatin Shah - Chief Medical Officer
Mike Mason - Chief Financial Officer
Stephen Mitchener - Chief Business Officer
Sharon Shacham - Chief Scientific Officer

Conference Call Participants

Maury Raycroft - Jefferies
Peter Lawson - Barclays
David Lebowitz - Morgan Stanley
Jonathan Chang - SVB Leerink
Colleen Kusy - Baird

Operator

Good morning. My name is Claudia Glentic [ph], and I will be the conference operator today. At this time, I would like to welcome everyone to the Karyopharm Therapeutics' Third Quarter 2021 Financial Results Conference Call. There will be a question-and-answer session to follow. Please be advised that this call is being recorded at the company's request.

I would now like to turn the call over to Jason Finkelstein of Argot Partners.

Jason Finkelstein

Thank you, Claudia, and thank you all for joining us on today's conference call to discuss Karyopharm's third quarter 2021 financial results and business update. Today, I'm joined by, Mr. Richard Paulson, President and Chief Executive Officer, Ms. Sohanya Cheng, Senior Vice President, Sales and Commercial Operations, Dr. Jatin Shah, Chief Medical Officer, Mr. Mike Mason, Chief Financial Officer; Mr. Stephen Mitchener, Chief Business Officer, and Dr. Sharon Shacham, Chief Scientific Officer.

During today's call as outlined on slide 2, Richard will provide some introductory remarks, Sohanya will provide an update on our XPOVIO commercial progress, Jatin will highlight recent pipeline investments and then Mike will discuss the third quarter financial results, highlights and guidance. We will conclude with some thoughts from Richard on upcoming milestones, and then we will move to the Q&A portion of the call.